Skip to content
Companies

TellBio

Microfluidic capture of circulating tumor cells from blood

Raised to date

$1M

of $1M offered across 1 Form D filing

Investors
6
Last filed
Mar 24, 2026

About

TellBio is an Andover, Massachusetts biotechnology company working on circulating tumor cells (CTCs), the cancer cells that break off a tumor and travel in the bloodstream. Its diagnostics platform uses microfluidics to isolate viable CTCs from a blood draw regardless of the primary tumor type, and is deployed as a research tool at medical centers internationally. A separate therapeutics program develops anti-cancer drug candidates from what the CTC work reveals about metastasis. The underlying technology is exclusively licensed from Massachusetts General Hospital, and several MGH researchers are company founders.

Isolates living, intact circulating tumor cells rather than fragments or cell-free DNA, and does so independently of tumor type, which supports both monitoring of metastatic progression and downstream functional testing of therapy response.

Funding

  • EquityFiled Mar 24, 2026Form D/A
    $1M/ $1M

Product

TellDx CTC System

Cancer diagnostics platform

A microfluidic diagnostics platform that isolates circulating tumor cells from patient blood samples, currently in use as a research tool at medical centers worldwide.

  • Microfluidic isolation of viable circulating tumor cells
  • Tumor-type agnostic capture
  • Monitors cancer progression and metastasis over time

Built for

Academic medical centers, cancer centers of excellence, and oncology research institutions; longer term, clinicians managing patients with metastatic cancer

People on file